Dose-related effects of salvinorin A in humans: Dissociative, hallucinogenic, and memory effects

Psychopharmacology

Volumn 226, Issue 2, 2013, Pages 381-392

  MacLean, Katherine A ^a   Johnson, Matthew W ^a   Reissig, Chad J ^a   Prisinzano, Thomas E ^b   Griffiths, Roland R ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS   (United States)

Author keywords

Dissociative; Hallucinogen; Human; Kappa opioid agonist; Psychedelic; Salvia divinorum; Salvinorin A

Indexed keywords

PSYCHEDELIC AGENT; SALVINORIN A;

ADULT; ARTICLE; COGNITION; CONTROLLED STUDY; FEMALE; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; MALE; MEMORY DISORDER; MENTAL DISSOCIATION; NORMAL HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RECALL; RECOGNITION;

ADMINISTRATION, INHALATION; ADULT; DISSOCIATIVE DISORDERS; DITERPENES, CLERODANE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALLUCINOGENS; HUMANS; MALE; MEMORY; RECEPTORS, OPIOID, KAPPA;

EID: 84877148871     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-012-2912-9     Document Type: Article

References (56)

1. Addy PH (2012) Acute and post-acute behavioral and psychological effects of salvinorin A in humans. Psychopharmacology (Berl) 220:195-204. doi: 10.1007/s00213-011-2470-6
2. Albertson DN, Grubbs LE (2009) Subjective effects of Salvia divinorum: LSD- or marijuana-like? J Psychoactive Drugs 41:213-217
3. Baggott MJ, Erowid E, Erowid F, Galloway GP, Mendelson J (2010) Use patterns and self-reported effects of Salvia divinorum: an internet-based survey. Drug Alcohol Depend 111:250-256
4. Baggott MJ, Coyle JR, Erowid E, Erowid F, Robertson LC (2011) Abnormal visual experiences in individuals with histories of hallucinogen use: a Web-based questionnaire. Drug Alcohol Depend 114:61-67. doi: 10.1016/j.drugalcdep.2010.09.006
5. Beck AT, Steer RA, Brown GK (1996) Manual for the beck depression inventory-II. Psychological Corporation, San Antonio
6. Braida D, Limonta V, Pegorini S, Zani A, Guerini-Rocco C, Gori E, Sala M (2007) Hallucinatory and rewarding effect of salvinorin A in zebrafish: kappa-opioid and CB1-cannabinoid receptor involvement. Psychopharmacol (Berl) 190:441-448. doi: 10.1007/s00213-006-0639-1
7. Braida D, Limonta V, Capurro V, Fadda P, Rubino T, Mascia P, Zani A, Gori E, Fratta W, Parolaro D, Sala M (2008) Involvement of kappa-opioid and endocannabinoid system on Salvinorin A-induced reward. Biol Psychiatry 63:286-292. doi: 10.1016/j.biopsych.2007.07.020
8. Cunningham CW, Rothman RB, Prisinzano TE (2011) Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev 63:316-347. doi: 10.1124/pr.110.003244
9. Derogatis LR (1993) BSI Brief Symptom Inventory: administration, scoring, and procedures manual. National Computer Systems, Minneapolis
10. Derogatis LR, Melisaratos N (1983) The brief symptom inventory: an introductory report. Psychol Med 13:595-605
11. Dittrich A (1998) The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry 31(Suppl 2):80-84
12. Fahn S, Tolosa E, Marín C (1993) Clinical rating scale for tremor. In: Jankovic J, Tolosa E (eds) Parkinson's disease and movement disorders. Williams & Wilkins, Baltimore, pp 225-234
13. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S (1998) The anatomy of conscious vision: an fMRI study of visual hallucinations. Nature 1:738-742
14. Gonzalez D, Riba J, Bouso JC, Gomez-Jarabo G, Barbanoj MJ (2006) Pattern of use and subjective effects of Salvia divinorum among recreational users. Drug Alcohol Depend 85:157-162. doi: 10.1016/j.drugalcdep.2006.04.001
15. Griffiths RR, Richards WA, McCann U, Jesse R (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacol (Berl) 187:268-283. doi: 10.1007/s00213-006-0457-5
16. Griffiths RR, Johnson MW, Richards WA, Richards BR, McCann UD, Jesse R (2011) Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. Psychopharmacol (Berl) 218:649-665. doi: 10.1007/s00213-011-2358-5
17. Hanes KR (2001) Antidepressant effects of the herb Salvia divinorum: a case report. J Clin Psychopharmacol 21:634-635
18. Hood RW, Ghorbani N, Watson PJ, Ghramaleki AH, Bing MN, Davison HK, Morris RJ, Williamson WP (2001) Dimensions of the mysticism scale: confirming the three-factor structure in the United States and Iran. J Sci Stud Relig 40:691-705
19. Isbell H, Bellevile RE, Fraser HF, Wikler A, Logan CR (1956) Studies on lysergic acid diethylamide (LSD-25). I. Effects in former morphine addicts and development of tolerance during chronic intoxication. Arch Gen Psychiatry 76:468-478
20. Jasinski DR (1977) Assessment of the abuse potential of morphine-like drugs (methods used in man). In: Martin WR (ed) Drug addiction. Springer, New York, pp 197-258
21. Johnson M, Richards W, Griffiths R (2008) Human hallucinogen research: guidelines for safety. J Psychopharmacol 22:603-620
22. Johnson MW, MacLean KA, Reissig CJ, Prisinzano TE, Griffiths RR (2011) Human psychopharmacology and dose-effects of salvinorin A, a kappa opioid agonist hallucinogen present in the plant Salvia divinorum. Drug Alcohol Depend 115:150-155. doi: 10.1016/j.drugalcdep.2010.11.005
23. Kelly BC (2011) Legally tripping: a qualitative profile of Salvia divinorum use among young adults. J Psychoactive Drugs 43:46-54
24. Kivell B, Prisinzano TE (2010) Kappa opioids and the modulation of pain. Psychopharmacol (Berl) 210:109-119. doi: 10.1007/s00213-010-1819-6
25. Kumor KM, Haertzen CA, Johnson RE, Kocher T, Jasinski D (1986) Human psychopharmacology of ketocyclazocine as compared with cyclazocine, morphine and placebo. J Pharmacol Exp Ther 238:960-968
26. Lange JE, Daniel J, Homer K, Reed MB, Clapp JD (2010) Salvia divinorum: effects and use among YouTube users. Drug Alcohol Depend 108:138-140. doi: 10.1016/j.drugalcdep.2009.11.010
27. Mansour A, Khachaturian H, Lewis ME, Akil H, Watson SJ (1988) Anatomy of CNS opioid receptors. Trends Neurosci 11:308-314
28. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetmine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245-258
29. McNair D, Lorr M, Droppleman L (1971) Manual for the profile of mood states. Education and industrial Testing Service, San Diego
30. Mello NK, Negus SS (2000) Interactions between kappa opioid agonists and cocaine. Preclinical studies. Ann N Y Acad Sci 909:104-132
31. Mendelson JE, Coyle JR, Lopez JC, Baggott MJ, Flower K, Everhart ET, Munro TA, Galloway GP, Cohen BM (2011) Lack of effect of sublingual salvinorin A, a naturally occurring kappa opioid, in humans: a placebo-controlled trial. Psychopharmacol (Berl) 214:933-939. doi: 10.1007/s00213-010-2103-5
32. Merrer JL, Becker JAJ, Befort K, Kieffer BL (2009) Reward processing by the opioid system in the brain. Physiol Rev 89:1379-1412. doi: 10.1152/physrev.00005.2009
33. Morani AS, Kivell B, Prisinzano TE, Schenk S (2009) Effect of kappa-opioid receptor agonists U69593, U50488H, spiradoline and salvinorin A on cocaine-induced drug-seeking in rats. Pharmacol Biochem Behav 94:244-249. doi: 10.1016/j.pbb.2009.09.002
34. Ott J (1995) Ethnopharmacognosy and human pharmacology of Salvia divinorum and salvinorin A. Curare 18:103-129
35. Ott J (1996) Pharmacotheon: entheogenic drugs, their plant sources and history, 2nd edn. Natural Products Co., Kennewick
36. Pahnke WN (1969) Psychedelic drugs and mystical experience. Int Psychiatry Clin 5:149-162
37. Perron BE, Ahmedani BK, Vaughn MG, Glass JE, Abdon A, Wu LT (2012) Use of Salvia divinorum in a nationally representative sample. Am J Drug Alcohol Abus 38:108-113. doi: 10.3109/00952990.2011.600397
38. Prisinzano TE (2005) Psychopharmacology of the hallucinogenic sage Salvia divinorum. Life Sci 78:527-531. doi: 10.1016/j.lfs.2005.09.008
39. Ranganathan M, Schnakenburg A, Skosnik PD, Cohen BM, Pittman B, Sewell RA, D'Souza DC (2012) Dose-related behavioral, subjective, endocrine, and psychophysiological effects of the κ opioid agonist salvinorin A in humans. Biol Psychiatry 72:871-879. doi: 10.1016/j.biopsych.2012.06.012
40. Reissig CJ, Carter LP, Johnson MW, Mintzer MZ, Klinedinst MA, Griffiths RR (2012) High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. Psychopharmacol (Berl). doi: 10.1007/s00213-012-2680-6
41. Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1-10
42. Roth BL, Baner K, Westkaemper R, Siebert D, Rice KC, Steinberg S, Ernsberger P, Rothman RB (2002) Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A 99:11934-11939. doi: 10.1073/pnas.182234399
43. Sheffler DJ, Roth BL (2003) Salvinorin A: the "magic mint" hallucinogen finds a molecular target in the kappa opioid receptor. Trends Pharmacol Sci 24:107-109
44. Siebert DJ (1994) Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol 43:53-56
45. Snodgrass JG, Corwin J (1988) Pragmatics of measuring recognition memory: applications to dementia and amnesia. J Exp Psychol Gen 117:34-50
46. Spielberger CD, Gorsuch RL, Lushene R, Vagg PR, Jacobs GA (1983) Manual for the state-trait anxiety inventory. Consulting Psychologist, Palo Alto
47. Strassman RJ, Qualls CR, Uhlenhuth EH, Kellner R (1994) Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale. Arch Gen Psychiatry 51:98-108
48. Studerus E, Kometer M, Hasler F, Vollenweider FX (2011) Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. J Psychopharmacol 25:1434-1452. doi: 10.1177/0269881110382466
49. Sumnall HR, Measham F, Brandt SD, Cole JC (2011) Salvia divinorum use and phenomenology: results from an online survey. J Psychopharmacol 25:1496-1507. doi: 10.1177/0269881110385596
50. Tejeda HA, Shippenburg TS, Henriksson R (2012) The dynorphin/κ- opioid receptor system and its role in psychiatric disorders. Cell Mol Life Sci 69:857-896. doi: 10.1007/s00018-011-0844-x
51. Turek IS, Soskin RA, Kurland AA (1974) Methylenedioxyamphetamine (MDA) subjective effects. J Psychedelic Drugs 6:7-14
52. Valdes 3rd LJ, Chang HM, Visger DC, Koreeda M (2001) Salvinorin C, a new neoclerodane diterpene from a bioactive fraction of the hallucinogenic Mexican mint Salvia divinorum. Org Lett 3:3935-3937
53. Vortherms TA, Roth BL (2006) Salvinorin A: from natural product to human therapeutics. Mol Interv 6:257-265. doi: 10.1124/mi.6.5.7
54. Walsh SL, Chausmer AE, Strain EC, Bigelow GE (2008) Evaluation of the mu and kappa opioid actions of butorphanol in humans through differential naltrexone blockade. Psychopharmacol (Berl) 196:143-155. doi: 10.1007/s00213-007-0948-z
55. Wu LT, Woody GE, Yang C, Li JH, Blazer DG (2011) Recent national trends in Salvia divinorum use and substance-use disorders among recent and former Salvia divinorum users compared with nonusers. Subst Abuse Rehabil 2011:53-68. doi: 10.2147/SAR.S17192
56. Zhang Y, Butelman ER, Schlussman SD, Ho A, Kreek MJ (2005) Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors. Psychopharmacol (Berl) 179:551-558. doi: 10.1007/s00213-004-2087-0